ライフサイエンスコーパス: Fanconi anemia

1 SCC cell lines derived from patients without Fanconi anemia.

2 sensitivity to DNA crosslinking agents, and Fanconi anemia.

3 associated with diseases such as cancer and Fanconi anemia.

4 and genetically heterogeneous BMF syndrome: Fanconi anemia.

5 y identified in hereditary breast cancer and Fanconi anemia.

6 associated with breast cancer and linked to Fanconi anemia.

7 , Li-Fraumeni and Bloom syndrome, as well as Fanconi anemia.

8 ailure is a nearly universal complication of Fanconi anemia.

9 ed to uncover a novel pathway linking HPV to Fanconi anemia.

10 opoietic stem cell defects characteristic of Fanconi anemia.

11 e sequence-related FANCJ helicase mutated in Fanconi anemia.

12 reatment, unlike cells from individuals with Fanconi anemia.

13 ny key features of the human genetic illness Fanconi anemia.

14 strand crosslinks is the defining feature in Fanconi anemia.

15 alive but die of malignancy associated with Fanconi anemia.

16 of malignancies, including breast cancer and Fanconi anemia.

17 for chemotherapy responses and prevention of Fanconi anemia.

18 hen biallelic, result in a severe subtype of Fanconi anemia.

19 at least sixteen FANC genes (FANCA-Q) cause Fanconi anemia, a disorder characterized by sensitivity

20 response in cells derived from patients with Fanconi anemia, a hereditary disorder characterized by b

21 Human FANCM has been linked to Fanconi anemia, a syndrome characterized by cancer predi

22 Fanconi anemia and Bloom syndrome are genomic instabilit

23 Cancer Cell, Schlacher et al. show that the Fanconi anemia and BRCA2 tumor suppressor pathways coope

24 Q motif DEAH box DNA helicase implicated in Fanconi anemia and breast cancer.

25 Inactivation of known Fanconi anemia and chromatid cohesion genes does explain

26 As in Fanconi anemia and dyskeratosis congenita, DBA is both a

27 se therefore establishes a disease model for Fanconi anemia and genetically links a regulator of nucl

28 These triggered processing by the Fanconi anemia and homologous recombination DNA repair p

29 re coordinated by the combined action of the Fanconi anemia and homologous recombination pathways.

30 hich is accompanied by downregulation of the Fanconi anemia and homologous recombination pathways.

31 cle arrest and uncovered a critical role for Fanconi anemia and homologous recombination proteins in

32 minor groove adducts normally recognized by Fanconi anemia and nucleotide excision repair machinery,

33 ndividuals with typical clinical features of Fanconi anemia and show that the cellular defects in the

34 g the pathogenesis of bone marrow failure in Fanconi anemia and suggest possible therapeutic approach

35 tudy included 330 patients (235 acquired, 85 Fanconi anemia, and 10 Diamond-Blackfan anemia) and thei

36 rth defects and bone marrow failure occur in Fanconi anemia, and may have implications for fetal well

37 es the S-phase accumulation of the BRCA1 and Fanconi anemia-associated DNA helicase FANCJ to sites of

38 omplex consists of eight FA proteins and two Fanconi anemia-associated proteins (FAAP24 and FAAP100).

39 Additional pathways, such as the Fanconi anemia-BRCA pathway, became perturbed only after

40 k repair pathway commonly referred to as the Fanconi anemia-BRCA pathway.

41 The Fanconi anemia/BRCA (FA/BRCA) pathway is a DNA repair pa

42 ream HSP90-dependent regulatory point in the Fanconi anemia/BRCA DSB/ICL repair pathway, illuminate t

43 tions in BRCA1, BRCA2, or other genes in the Fanconi anemia/BRCA pathway, and these tumors have been

44 ckdown suppresses the genomic instability of Fanconi Anemia/BRCA pathway-deficient cells.

45 a DNA helicase that is genetically linked to Fanconi anemia, breast cancer, and ovarian cancer.

46 rare disorder related to cohesinopathies and Fanconi anemia, caused by bi-allelic mutations in DDX11.

47 Here, by complementing a null FA-P Fanconi anemia cell line with SLX4 mutants that specific

48 lease-independent L1 retrotransposition in a Fanconi anemia cell line.

49 In Fanconi anemia complementation gene M (FANCM), nonsense

50 The Fanconi anemia complementation group A (FANCA) gene is o

51 Intriguingly, ICL repair protein, Fanconi anemia complementation group A protein (FANCA),

52 Fanconi anemia complementation group C (FANCC) protein i

53 rcomes inherent TNFalpha hypersensitivity of Fanconi anemia complementation group C deficient progeni

54 tivates the FA pathway by monoubiquitinating Fanconi anemia complementation group D2 (FANCD2) for the

55 complex acts on DNA-bound, monoubiquitinated Fanconi anemia complementation group D2 (FANCD2) protein

56 itivity to replication-blocking lesions than Fanconi anemia complementation group L (FANCL)-null muta

57 We show that Fml1, the Fanconi anemia complementation group M (FANCM)-ortholog

58 which encodes the DNA translocase FANCM (for Fanconi anemia complementation group M), which is requir

59 l cells depleted of alphaIISp by siRNA or in Fanconi anemia, complementation group A (FA-A) cells, wh

60 ules using TLR agonist-stimulated FANCC- and Fanconi anemia, complementation group A (FANCA)-deficien

61 Fanconi anemia, complementation group C (FANCC)-deficien

62 his model leads to the discovery that Fancl (Fanconi anemia, complementation group L) is downregulate

63 AAP20 UBZ is required for recruitment of the Fanconi anemia complex to interstrand DNA crosslink site

64 ger module, toward ubiquitin recognition and Fanconi anemia complex-mediated DNA interstrand crosslin

65 Rev1-pol zeta recruitment requires the Fanconi anemia core complex but not FancI-FancD2.

66 FAAP20 is an integral component of the Fanconi anemia core complex that mediates the repair of

67 s essential for viability, yet patients with Fanconi anemia-D1 subtype are born alive with biallelic

68 Potential implication for treatment of Fanconi anemia-deficient tumors by their sensitization t

69 ulator of nuclease incision complexes to the Fanconi anemia DNA crosslink repair pathway.

70 way analysis, we observed that both cAMP and Fanconi anemia DNA damage repair pathways were affected

71 terstrand cross-link (ICL) repair within the Fanconi anemia DNA damage response (DDR) pathway.

72 ive in both homologous recombination and the Fanconi anemia DNA damage response pathways.

73 plicate a functional interaction between the Fanconi anemia DNA repair and FOXO3a pathways in HSC mai

74 g enzyme that promotes the activation of the Fanconi anemia DNA repair pathway and facilitates replic

75 s the E2 ubiquitin-conjugating enzyme of the Fanconi anemia DNA repair pathway and it is overexpresse

76 t data have shown that HIV-1 Vpr targets the Fanconi anemia DNA repair pathway by interacting with an

77 The Fanconi anemia DNA repair pathway consists of an anchor

78 pport the development of embryos lacking the Fanconi anemia DNA repair pathway gene Fanca.

79 eins and that the ability to dysregulate the Fanconi anemia DNA repair pathway is an essential functi

80 at the ability to dysregulate members of the Fanconi anemia DNA repair pathway is essential for HIV/S

81 The Fanconi anemia DNA repair pathway is pivotal for the eff

82 link colorectal cancer predisposition to the Fanconi anemia DNA repair pathway, supporting the connec

83 1 exonuclease complex that forms part of the Fanconi anemia DNA repair pathway.

84 and in the unfractionated BM of healthy and Fanconi anemia donors, resulting in the correction of CD

85 The 4 most frequent syndromes are Fanconi anemia, dyskeratosis congenita, Diamond Blackfan

86 olved diagnosis after medical evaluation and Fanconi anemia exclusion.

87 Fanconi Anemia (FA) and Bloom Syndrome share overlapping

88 Fanconi anemia (FA) and Bloom's syndrome (BS) are rare h

89 FANCJ mutations are linked to Fanconi anemia (FA) and increase breast cancer risk.

90 er of repair proteins including those of the Fanconi anemia (FA) and the homologous recombination (HR

91 Children with Fanconi anemia (FA) are a paradigm for extreme SCC susce

92 Bloom's syndrome (BS) and Fanconi anemia (FA) are autosomal recessive disorders ch

93 Fanconi Anemia (FA) clinical phenotypes are heterogenous

94 In response to DNA cross-linking damage, the Fanconi anemia (FA) core complex activates the FA pathwa

95 so associates with FANCM, a component of the Fanconi anemia (FA) core complex that is important for r

96 tute a complex involved in the activation of Fanconi anemia (FA) DNA damage response mechanism, but n

97 Defects in the Fanconi anemia (FA) DNA damage-response pathway result i

98 The Fanconi Anemia (FA) DNA repair pathway is essential for

99 Herein, we identify a member of the Fanconi anemia (FA) DNA repair pathway, FANCI, as a key

100 We show that central components of the Fanconi anemia (FA) DNA repair pathway, the tumor suppre

101 Fancd2 is a component of the Fanconi anemia (FA) DNA repair pathway, which is frequen

102 nt for replication fork stabilization by the Fanconi anemia (FA) DNA repair pathway.

103 ietic stem cell function and are part of the Fanconi anemia (FA) double-strand break DNA repair pathw

104 oteins disabled in the cancer-prone disorder Fanconi anemia (FA) ensure the maintenance of chromosoma

105 d the double-stranded break (DSB) repair and Fanconi anemia (FA) factors active in the S/G2 phase as

106 Previous Fanconi anemia (FA) gene therapy studies have failed to

107 It has recently been designated as a Fanconi anemia (FA) gene, following the discovery of two

108 c stem and progenitor cells with inactivated Fanconi anemia (FA) genes, FANCA and FANCC, are hypersen

109 Similar to mutations in Fanconi anemia (FA) genes, unc-84 mutants and human cell

110 Here, we establish that the cellular Fanconi anemia (FA) genomic stability pathway is exploit

111 Patients with Fanconi anemia (FA) have a high risk of developing acute

112 Genes mutated in patients with Fanconi anemia (FA) interact with the DNA repair genes B

113 Fanconi anemia (FA) is a cancer predisposition syndrome

114 Fanconi anemia (FA) is a cancer predisposition syndrome

115 Fanconi anemia (FA) is a chromosome instability syndrome

116 Fanconi anemia (FA) is a chromosome instability syndrome

117 Fanconi anemia (FA) is a disease of DNA repair character

118 Fanconi anemia (FA) is a DNA repair syndrome generated b

119 Fanconi anemia (FA) is a genetic disease characterized b

120 Fanconi anemia (FA) is a genetic disease of bone marrow

121 Fanconi anemia (FA) is a genetic disorder associated wit

122 Fanconi anemia (FA) is a genetic disorder characterized

123 Fanconi anemia (FA) is a genetically heterogeneous disor

124 Fanconi anemia (FA) is a genetically heterogeneous disor

125 Fanconi anemia (FA) is a genome instability syndrome cha

126 Fanconi anemia (FA) is a genome instability syndrome cha

127 Fanconi anemia (FA) is a genome instability syndrome tha

128 Fanconi anemia (FA) is a heterogenous genetic disease wi

129 Fanconi anemia (FA) is a human recessive genetic disease

130 Fanconi anemia (FA) is a multigenic disease of bone marr

131 Fanconi anemia (FA) is a rare bone marrow failure disord

132 Fanconi anemia (FA) is a rare disease characterized by c

133 Fanconi anemia (FA) is a rare genetic disease characteri

134 Fanconi anemia (FA) is a rare genetic disorder associate

135 Fanconi anemia (FA) is a rare genetic disorder caused by

136 Fanconi anemia (FA) is a rare genetic disorder character

137 Fanconi anemia (FA) is a rare genetic disorder character

138 Fanconi anemia (FA) is a rare genetic disorder character

139 Fanconi anemia (FA) is a rare inherited disorder clinica

140 Fanconi anemia (FA) is a recessive genetic disease chara

141 Fanconi anemia (FA) is a recessive syndrome characterize

142 Fanconi anemia (FA) is a recessive X-linked and autosoma

143 Fanconi anemia (FA) is an autosomal recessive genetic di

144 Fanconi anemia (FA) is an inherited bone marrow failure

145 Fanconi anemia (FA) is an inherited bone marrow failure

146 Fanconi anemia (FA) is an inherited bone marrow failure

147 Fanconi anemia (FA) is an inherited cancer predispositio

148 Fanconi anemia (FA) is an inherited chromosomal instabil

149 Fanconi anemia (FA) is an inherited chromosomal instabil

150 Fanconi anemia (FA) is an inherited disease characterize

151 Fanconi anemia (FA) is an inherited disorder in which mu

152 Fanconi anemia (FA) is an inherited DNA repair disorder

153 Fanconi anemia (FA) is an inherited genetic disorder ass

154 Fanconi anemia (FA) is characterized by a progressive bo

155 Fanconi anemia (FA) is the most common genetic cause of

156 Fanconi anemia (FA) is the most frequent inherited cause

157 Fanconi anemia (FA) macrophages were hypersensitive to t

158 the bone marrow failure (BMF) mechanisms in Fanconi anemia (FA) may improve current therapeutic stra

159 Similar to the reported Fanconi anemia (FA) mouse model, chromosomal instability

160 Fanconi anemia (FA) nuclear core complex is a multiprote

161 ICLs can be repaired by the Fanconi anemia (FA) pathway and through FA-independent p

162 Fanconi anemia (FA) pathway genes are important tumor su

163 viously reported intrinsic activation of the Fanconi anemia (FA) pathway in a tumor-prone mouse model

164 Despite a well-defined role for the Fanconi anemia (FA) pathway in mediating DNA repair, the

165 The Fanconi anemia (FA) pathway involved in DNA crosslink re

166 The Fanconi anemia (FA) pathway is essential for the repair

167 The Fanconi anemia (FA) pathway is essential for the repair

168 We find that the Fanconi Anemia (FA) pathway is required for dsDonor HDR

169 The Fanconi anemia (FA) pathway is the principal mechanism f

170 Fanconi anemia (FA) pathway members, FANCD2 and FANCI, c

171 The Fanconi anemia (FA) pathway participates in interstrand

172 The Fanconi anemia (FA) pathway plays a central role in the

173 Moreover, we have identified several new Fanconi anemia (FA) pathway SNPs that are likely to modu

174 the possibility that HELQ is involved in the Fanconi anemia (FA) pathway, a dominant mechanism for in

175 Several pathways, including the Fanconi anemia (FA) pathway, can faithfully repair ICLs

176 Several proteins in the BRCA-Fanconi anemia (FA) pathway, such as FANCJ, BRCA1, and F

177 The Fanconi anemia (FA) pathway, which promotes error-free r

178 CI-FANCD2 heterodimer, a central step in the Fanconi anemia (FA) pathway.

179 tivates Trans-Lesion Synthesis (TLS) and the Fanconi Anemia (FA) pathway.

180 Fanconi anemia (FA) patients exhibit bone marrow failure

181 hematopoietic cell transplantation (HCT) for Fanconi anemia (FA) patients resulted in excessive morbi

182 Bone marrow failure (BMF) in Fanconi anemia (FA) patients results from dysfunctional

183 The Fanconi anemia (FA) protein network is necessary for rep

184 In addition, FANCD2, another Fanconi Anemia (FA) protein, is also required for CC for

185 tes faithful DNA replication consists of the Fanconi anemia (FA) proteins.

186 Fanconi anemia (FA) represents a paradigm of rare geneti

187 However, the involvement of Fanconi Anemia (FA) signaling, a unique genetic model sy

188 skews HSC differentiation in mouse models of Fanconi anemia (FA), a genetic disorder associated with

189 athogenesis of many human diseases including Fanconi anemia (FA), a genetic disorder associated with

190 Defective DNA repair causes Fanconi anemia (FA), a rare childhood cancer-predisposin

191 is the predominant clinical manifestation of Fanconi anemia (FA), a rare, recessively inherited disor

192 d activities of translesion synthesis (TLS), Fanconi anemia (FA), and homologous recombination repair

193 icient mice, while phenotypically resembling Fanconi anemia (FA), are also hypersensitive to replicat

194 Impaired DNA crosslink repair leads to Fanconi anemia (FA), characterized by a unique manifesta

195 suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA g

196 he only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to si

197 t underlying progressive BM failure (BMF) in Fanconi anemia (FA), the most frequent inherited BMF dis

198 plex-dependent ubiquitin recognition and the Fanconi anemia (FA)-BRCA ICL repair network.

199 The Fanconi anemia (FA)-BRCA pathway is critical for the rep

200 ell proliferation, whereas the expression of Fanconi anemia (FA)-complex genes was correlated with el

201 line mutations in RAD51C are known to cause Fanconi anemia (FA)-like disorder and breast and ovarian

202 Current methods for detecting mutations in Fanconi anemia (FA)-suspected patients are inefficient a

203 of unrelated bone marrow transplantation in Fanconi anemia (FA).

204 other cancers, and biallelic mutations cause Fanconi anemia (FA).

205 mutations in their corresponding genes cause Fanconi anemia (FA).

206 ations in these genes clinically manifest as Fanconi anemia (FA).

207 an cure bone marrow failure in patients with Fanconi anemia (FA).

208 mutated in breast and pancreatic cancers and Fanconi anemia (FA).

209 ociated with the genome instability syndrome Fanconi anemia (FA).

210 cers as well as bone marrow failure disorder Fanconi anemia (FA).

211 ypersensitivity is a characteristic trait of Fanconi anemia (FA).

212 ess required to suppress diseases, including Fanconi anemia (FA).

213 ective in the cancer predisposition syndrome Fanconi anemia (FA).

214 e and hyperpigmentation, now better known as Fanconi anemia (FA).

215 ould affect the severity of BRCA1-associated Fanconi anemia (FA).

216 marrow failure syndromes: (1) defects in the Fanconi anemia (FA)/BRCA DNA repair pathway, (2) defects

217 cells and its corporation with the canonical Fanconi anemia (FA)/BRCA pathway remain unclear.

218 Surprisingly, depleting BRCA1 or FANCD2 (Fanconi anemia [FA] proteins) or BRG1, a mSWI/SNF subuni

219 etic screens for homologous recombination or Fanconi anemia factors indicates that our evolution-base

220 enamed here as FANCP) cause a new subtype of Fanconi anemia, Fanconi anemia-P.

221 deleterious c.2715 + 1G > A mutation in the Fanconi anemia gene, FANCD2, was over two times more com

222 Mutations in thirteen distinct Fanconi anemia genes have been shown to interfere with t

223 describe a previously unappreciated role of Fanconi anemia group A protein (Fanca) during the endomi

224 Of the fifteen FA proteins, Fanconi anemia group C (FANCC) is one of eight FA core c

225 Monoubiquitination of Fanconi anemia group D2 protein (FANCD2) by the multisub

226 The Fanconi anemia group J (FANCJ) helicase partners with th

227 t other DNA helicases [Bloom syndrome (BLM), Fanconi anemia group J (FANCJ), RECQ1, RecQ, UvrD, or Dn

228 3 ubiquitin-protein ligase RNF168-deficient, Fanconi anemia group J protein (FACJ, BRIP1)-deficient,

229 ion of aldehydes as endogenous genotoxins in Fanconi anemia has provided new insight into disease cau

230 Since patients with Fanconi anemia have a high risk to develop HNSCC, we inv

231 marrow failure and cancer susceptibility of Fanconi anemia have been unclear.

232 how that Mph1, the budding yeast ortholog of Fanconi anemia helicase FANCM, prevents precocious DSB s

233 Fanconi anemia hematopoietic stem cells display poor sel

234 ceptibility gene, BRCA2, are associated with Fanconi anemia, implying that some persons who inherit 2

235 Examining the cancer predisposition syndrome Fanconi anemia in depth revealed that mutant FANCA prote

236 y inactivation underlies CIN in HNSCC of non-Fanconi anemia individuals.

237 Fanconi anemia is a cancer predisposition syndrome cause

238 Fanconi anemia is a genetic disease resulting in bone ma

239 Fanconi anemia is a genetic disorder resulting from bial

240 Fanconi anemia is a rare genetic disorder that can lead

241 Fanconi anemia is a rare recessive disorder characterize

242 The genomic instability syndrome Fanconi anemia is caused by mutations in any of at least

243 The human hereditary disease Fanconi anemia leads to severe symptoms, including devel

244 homologous recombination, in a patient with Fanconi anemia-like phenotype.

245 We excluded Fanconi anemia, mutations of telomere maintenance, and a

246 ni anemia, we propose collaborations between Fanconi anemia, NER, and MMR are necessary to initiate c

247 FANCD2 and FANCI function together in the Fanconi anemia network of deoxyribonucleic acid (DNA) cr

248 disabling the mismatch, nucleotide excision, Fanconi anemia, nonhomologous end joining, or translesio

249 ndently of the previously identified anti-CO Fanconi anemia of complementation group M (FANCM) helica

250 me; cancer risks appear lower in DBA than in Fanconi anemia or dyskeratosis congenita.

251 demonstrated that chronic GVHD (P = .02) and Fanconi anemia (P = .03) negatively impacted survival.

252 ANCP) cause a new subtype of Fanconi anemia, Fanconi anemia-P.

253 owever, were incomplete or low magnitude for Fanconi anemia pathway (FANC) gene mutations relevant to

254 Rodriguez and D'Andrea introduce the Fanconi anemia pathway and its role in DNA repair and ot

255 ts elucidate the functional link between the Fanconi anemia pathway and the recombination machinery d

256 y in cells lacking FANCD2, a mediator of the Fanconi anemia pathway for ICL repair.

257 We found that MECP2 regulates the DNA repair Fanconi anemia pathway in HSCs.

258 we investigated whether and to which extent Fanconi anemia pathway inactivation underlies CIN in HNS

259 Thus, when the Fanconi anemia pathway is defective, WRN helicase inhibi

260 CD2 and provide a novel mechanism of how the Fanconi anemia pathway modulates DNA damage response and

261 lementation group D2 (FANCD2) protein in the Fanconi anemia pathway of the DNA damage response.

262 dy, a role that we show is not shared by the Fanconi anemia pathway or the Slx4-Slx1 nuclease also in

263 define the molecular mechanism by which the Fanconi anemia pathway promotes a key event in replicati

264 ced downregulation of a key component of the Fanconi anemia pathway, FANCD2 through mTOR regulation o

265 of the defects seen in cells impaired in the Fanconi anemia pathway, including a pronounced G2-M cell

266 e that FANCL, the E3 ubiquitin ligase of the Fanconi anemia pathway, is constitutively targeted for d

267 s recombination, postreplication repair, the Fanconi anemia pathway, polymerase beta, and FEN1 are cr

268 Incisions depend critically on the Fanconi anemia pathway, whose activation involves ubiqui

269 mic damage during replication, especially in Fanconi anemia pathway-deficient cells.

270 this function independently of the classical Fanconi anemia pathway.

271 t is important for R-loop suppression by the Fanconi Anemia pathway.

272 FANCD2 monoubiquitination, a key step of the Fanconi anemia pathway.

273 Moreover, Forkhead box signaling and Fanconi anemia pathways were specifically enriched in PS

274 ment, including single-strand DNA repair and Fanconi anemia pathways, suggesting that DNA repair afte

275 Here, we characterized two Fanconi anemia patient mutations, R251C and Q255H, that

276 the acquired AA patients is 82%, and for the Fanconi anemia patients it is 58% (P = .01).

277 Thus, cells from Fanconi anemia patients, which lack this critical pathwa

278 found to be mutated in approximately 60% of Fanconi anemia patients.

279 separately and with loss of staining for the Fanconi anemia protein FANCD2 (corrected Fisher's exact

280 show that the monoubiquitinated form of the Fanconi Anemia protein FANCD2 acts in opposition to the

281 Here we show that the Fanconi anemia protein Fancd2 and stress transcriptional

282 The USP1/UAF1 complex deubiquitinates the Fanconi anemia protein FANCD2, thereby promoting homolog

283 The SLX4 Fanconi anemia protein is a tumor suppressor that may ac

284 The Fanconi anemia protein PALB2, also known as FANCN, prote

285 The Fanconi anemia protein SLX4 assembles a genome and telom

286 SLX4, the newly identified Fanconi anemia protein, FANCP, is implicated in repairin

287 epair activities that are independent of the Fanconi anemia proteins and that this activity is redund

288 phenotype raises the question of whether the Fanconi anemia proteins are stabilized or recruited as p

289 acentric chromosomes, papillar cells require Fanconi anemia proteins FANCD2 and FANCI, as well as Blm

290 rons, from 27 samples from the International Fanconi Anemia Registry at The Rockefeller University.

291 iants, from 16 families of the International Fanconi Anemia Registry.

292 FAN1 is a major component of the Fanconi anemia-related pathway of DNA damage response (D

293 r onset and a loss of blood cells similar to Fanconi anemia.See related article by Park et al., p.

294 utations in the PALB2 tumor suppressor cause Fanconi anemia subtype FA-N, monoallelic mutations predi

295 ) have been identified in patients, with the Fanconi anemia subtype J (FA-J) resulting from homozygou

296 sition to breast and pancreatic cancer or to Fanconi Anemia subtype N.

297 ical processes, including DNA damage repair (Fanconi anemia), telomere maintenance (dyskeratosis cong

298 promising initial hit compound targeting the Fanconi anemia ubiquitin-conjugating enzyme Ube2T and de

299 iven that, mutations in XPF can also lead to Fanconi anemia, we propose collaborations between Fancon

300 Defects in ICL repair result in Fanconi anemia, which is characterized by bone marrow fa